HSBC Holdings
URGN icon

HSBC Holdings’s UroGen Pharma URGN Stock Holding History

HSBC Holdings’s Portfolio URGN Stock Details URGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-10,316
Closed -$236K – 3245
2025
Q4 		$236K Sell
10,316
-3,565
-26% -$77.3K ﹤0.01% 2621
2025
Q3 		$270K Buy
13,881
+149
+1% +$2.68K ﹤0.01% 2370
2025
Q2 		$187K Buy
+13,732
New +$132K ﹤0.01% 2706
2024
Q2 		– Sell
-52,954
Closed -$794K – 3177
2024
Q1 		$794K Buy
+52,954
New +$866K ﹤0.01% 1882

Other funds holding URGN

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
JFG
Jefferies Financial Group New York $14.6B AUM 40.95% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return
SG Americas Securities
SG Americas Securities New York $92.9B AUM 36.98% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

HSBC Holdings's URGN Position: Q1 2026 in Review

HSBC Holdings sold out of UroGen Pharma (URGN) in Q1 2026, closing a stake of 10,316 shares — an estimated $236K sold.

HSBC Holdings first reported a position in URGN in Q1 2024 and held it in 4 quarters. The position peaked at $794K in Q1 2024. 173 funds tracked by Wall St. Rank hold URGN as of Q1 2026.

  • HSBC Holdings reported no remaining UroGen Pharma position as of Q1 2026 after selling out during the quarter.
  • HSBC Holdings sold 10,316 UroGen Pharma shares in Q1 2026, an estimated $236K.
  • HSBC Holdings first reported a position in UroGen Pharma in Q1 2024 and held it in 4 quarters.
  • HSBC Holdings's UroGen Pharma position peaked at $794K in Q1 2024.
  • 173 funds tracked by Wall St. Rank held UroGen Pharma as of Q1 2026.

Based on HSBC Holdings's 13F filing for Q1 2026, filed 30 Apr 2026.